Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus HYFTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus HYFTOR.
ARAZLO vs HYFTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
HYFTOR (solithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation and inhibiting translation. It also exhibits anti-inflammatory effects by modulating cytokine production and neutrophil activity.
Topical: Apply 0.045% gel once daily to affected areas of the face.
0.5% gel, apply a thin layer to the treatment area once daily at bedtime. Duration: 4-8 weeks.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 5.5 hours (range: 3.2–9.1 h), supporting twice-daily dosing.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism; minimal renal excretion (<1% as unchanged drug). Eliminated via feces (84%) and urine (4%) as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid